Friday, October 7, 2022

TELUS completes the acquisition of in-person solutions firm LifeWorks

0
TELUS Corporation has completed of the acquisition of LifeWorks Inc. (LifeWorks), a provider digital and in-person solutions that support the total wellbeing of individuals – mental, physical, financial and social, solidifying TELUS Health as one of the largest firms providing digital-first health and wellness solutions that empower individuals to live their healthiest lives.

Aster Guardians Global Nursing Award 2023 open for nominations

0
In its continued efforts to recognize the contribution of nurses to mankind and to the healthcare community, Aster DM Healthcare has announced the next edition of the Aster Guardians Global Nursing Award. The award invites registered nurses from across the world to apply for the award by submitting nomination of their work on the mentioned site directly.

US military veterans to benefit from Osteopore’s ground-breaking implants

0
An Aussie-Singaporean ASX-listed bone and tissue regeneration firm will help US military veterans suffering trauma injuries and congenital defects with its 3D-printed bioresorbable implants. Osteopore’s US based distributor, Bioplate Inc, has secured a non-exclusive distribution agreement with MellingMedical LLC which will see its FDA-cleared products sold to healthcare facilities operated by the US federal govt – at over 500 locations in the country.

The polypill reduces cardiovascular mortality by 33%, reveals SECURE

0
The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack. The polypill reduces mortality from cardiovascular causes in this population by 33% according to SECURE study, coordinated by the Spanish National Center for Cardiovascular Research (CNIC). The results were aired in a session at the European Society of Cardiology meeting (ESC 2022) in Barcelona and published in The New England Journal of Medicine (NEJM).

Health tech firm Covetrus names Margie Pritchard General Counsel

0
Covetrus® (NASDAQ: CVET), a global player in animal-health technology and services, announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management.

Fighting medicines that kill in Africa: A collaborative and integrated approach

0
The traffic in falsified and substandard medicines (FSMs) is a severe public health problem for individuals, families, communities and countries by depriving them of access to affordable and good medicines. Although there are encouraging signs of growth in local pharmaceutical production on the African continent, a 2019 study indicates that only 10-30% of medicines consumed in sub-Saharan Africa are manufactured locally according to McKinsey, 2020.

Mind Medicine Australia launches Australia’s largest philanthropic grant

0
Mind Medicine Australia (MMA) is excited to announce a fund to support the development of observational trials into psychedelic-assisted therapies to treat a range of mental illnesses. The initial commitment of funding of $1m will be provided by the Hunt Family Foundation with additional funding sought from other philanthropists. Applications will be managed by relevant members of the scientific and clinical advisory panel of Mind Medicine Australia chaired by Professor David Nutt, Head of Neuropsychopharmacology at Imperial College London.

AdvanCell announces AUD$18m Series B funding led by Morningside

0
AdvanCell, an Aussie radiopharmaceutical firm with tech for a revolutionary cancer treatment called Targeted Alpha Therapy, closed an AUD$18 million Series B funding led by Morningside. Targeted Alpha Therapies represent the most exciting opportunity to treat untreatable cancers. The tech harnesses the decay and radiochemical properties of certain elements, in combination with targeting molecules, to deliver cell-killing radiation to the tumour cell.

Aspen Medical onboards Oracle cloud apps to bolster critical health services

0
Aussie healthcare solutions provider Aspen medical has worked with Oracle to consolidate its business processes across HR, finance, and projects in support of its extraordinary work. A big part of the Aussie-based firm’s business is responding to medical crises and saving lives, often in the most remote, under-resourced parts, deploying teams on very short notice.

Prototyping and manufacturing facility to accelerate medtech start-ups

0
Entrepreneurs and researchers will collaborate to develop new medical technologies for healthcare and diagnostics thanks to a new $16.7 million funding facility based at RMIT University. The Victorian Medical Device Prototyping and Scale-Up Facility has been announced today by Minister for Higher Education Gayle Tierney, supported through $12.7 million in funding from the Victorian Higher Education State Investment Fund (VHESIF).